Core Viewpoint - Tron is set to challenge Wall Street's perception of legitimate corporate assets through its strategic move to incorporate its native cryptocurrency TRX as a reserve asset, which could have broader implications beyond the company itself [1]. Group 1: Company Strategy and Developments - SRM Entertainment announced its rebranding to Tron Inc, adopting a treasury strategy centered around TRX, supported by a $100 million private investment that could rise to $210 million if warrants are fully exercised [1]. - The strategy aims to test TRX as a company reserve asset, marking a significant shift as Tron Inc would be the first U.S. company to use its blockchain's native token as a corporate reserve [5][6]. - Following the announcement, TRX experienced a 5% increase in value, indicating market interest in the new strategy [3]. Group 2: Market Context and Comparisons - More companies are integrating cryptocurrencies into their treasuries, inspired by firms like Strategy (formerly MicroStrategy), which has promoted aggressive Bitcoin acquisition strategies [3]. - However, the effectiveness of such treasury strategies is diminishing, as merely announcing a cryptocurrency treasury no longer guarantees a surge in stock prices [3]. - TRX's market capitalization reached $26.2 billion as of June 17, ranking it eighth among cryptocurrencies, but it lacks significant institutional demand and has lower trading volumes compared to Bitcoin and other treasury coins [6]. Group 3: Risks and Concerns - The plan to use TRX as a reserve asset introduces a feedback loop risk; if market confidence in Tron Inc wanes, TRX's price could drop, further impacting the perceived value of the company [5]. - Concerns have been raised regarding the potential for regulatory scrutiny, especially since the SEC has previously accused Tron and its founder of selling unregistered securities [14]. - The involvement of politically connected individuals, such as Eric Trump, in the new TRX financial company has raised questions about the independence and integrity of the venture [12][13].

据 IPO 早 知 道 消 息 ， 近 日 ， 纳 斯 达 克 生 物 医 药 公 司 Ikena Oncology （ IKNA.US ） 和 创 响 生 物 （Inmagene）宣布双方已达成最终合并协议。创响生物将反向收购Ikena。 此次合并将产生1.75亿美元资金，其中包括7500万美元超额认购的PIPE私募融资。 Ikena已与 Deep Track Capital、Foresite Capital、RTW Investments等新投资人达成认购协议 ，此外， Ikena 原 有 股 东 BVF Partners LP 、 Blue Owl Healthcare Opportunities 、 Omega Funds 和 OrbiMed等 也参与了此次PIPE认购。 合并预计将于2025年年中完成。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 合并后的公司将专注于开发针对OX40的单克隆抗体（mAb）IMG-007，用于治疗特应性皮炎。合 并后的公司计划以"ImageneBio"的名称运营，并在纳斯达克以"IMA"为股票代码进行交易。 合并和融资完成后，Ikena股 ...